IN2012DN01920A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01920A
IN2012DN01920A IN1920DEN2012A IN2012DN01920A IN 2012DN01920 A IN2012DN01920 A IN 2012DN01920A IN 1920DEN2012 A IN1920DEN2012 A IN 1920DEN2012A IN 2012DN01920 A IN2012DN01920 A IN 2012DN01920A
Authority
IN
India
Prior art keywords
proliferative
antibodies
treatment
well
immune disorders
Prior art date
Application number
Inventor
Xiao Min Schebye
Grigory P Ermakov
Douglas J Hodges
Leonard G Presta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IN2012DN01920A publication Critical patent/IN2012DN01920A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
IN1920DEN2012 2009-09-03 2010-08-31 IN2012DN01920A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23966709P 2009-09-03 2009-09-03
US30776710P 2010-02-24 2010-02-24
US31395510P 2010-03-15 2010-03-15
PCT/US2010/047248 WO2011028683A1 (en) 2009-09-03 2010-08-31 Anti-gitr antibodies

Publications (1)

Publication Number Publication Date
IN2012DN01920A true IN2012DN01920A (en) 2015-07-24

Family

ID=43649600

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1920DEN2012 IN2012DN01920A (en) 2009-09-03 2010-08-31
IN2826DEN2015 IN2015DN02826A (en) 2009-09-03 2010-08-31

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2826DEN2015 IN2015DN02826A (en) 2009-09-03 2010-08-31

Country Status (22)

Country Link
US (3) US8709424B2 (en)
EP (2) EP2473531A4 (en)
JP (3) JP6294585B2 (en)
KR (2) KR101790802B1 (en)
CN (2) CN102574924A (en)
AU (1) AU2010289677B2 (en)
BR (1) BR112012004823B1 (en)
CA (2) CA2772613C (en)
CY (1) CY1123404T1 (en)
DK (1) DK3023438T3 (en)
ES (1) ES2788869T3 (en)
HR (1) HRP20200720T1 (en)
HU (1) HUE049825T2 (en)
IN (2) IN2012DN01920A (en)
LT (1) LT3023438T (en)
MX (1) MX340953B (en)
PL (1) PL3023438T3 (en)
PT (1) PT3023438T (en)
RU (2) RU2595409C2 (en)
SG (1) SG178991A1 (en)
SI (1) SI3023438T1 (en)
WO (1) WO2011028683A1 (en)

Families Citing this family (561)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
PL2173379T3 (en) 2007-07-02 2016-02-29 Oncomed Pharm Inc Compositions and methods for treating and diagnosing cancer
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
CN107469077A (en) 2008-04-11 2017-12-15 中外制药株式会社 The antigen binding molecules combined repeatedly with the antigen of multiple molecules
ES2788869T3 (en) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anti-GITR antibodies
BR112013013354A2 (en) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha antigen-binding molecule capable of binding to a plurality of antigen molecules repeatedly
CN107903325B (en) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use
EP3401329A1 (en) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101566539B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th2 cell and use thereof
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
WO2014030728A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 Fcγriib-specific fc region variant
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
PL2925350T3 (en) 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson FUSION PROTEINS FOR MODULATING LYMPHOCYTES T REGULATORS AND EFFECTORS
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
BR112016002614B8 (en) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Immunocytokine and pharmaceutical composition
AR097306A1 (en) * 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) * 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
EP3043820A4 (en) 2013-09-13 2017-07-12 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
CA2920686C (en) * 2013-09-13 2022-12-06 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
CN108558871B (en) 2013-12-24 2022-02-18 百时美施贵宝公司 Tricyclic compounds as anticancer agents
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
EA201691765A1 (en) 2014-03-14 2016-12-30 Новартис Аг ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS
JP2017513818A (en) 2014-03-15 2017-06-01 ノバルティス アーゲー Treatment of cancer using chimeric antigen receptors
TWI714525B (en) 2014-03-24 2021-01-01 瑞士商諾華公司 Monobactam organic compounds for the treatment of bacterial infections
WO2015157252A1 (en) 2014-04-07 2015-10-15 BROGDON, Jennifer Treatment of cancer using anti-cd19 chimeric antigen receptor
SMT202100116T1 (en) 2014-05-28 2021-05-07 Agenus Inc Anti-gitr antibodies and methods of use thereof
EP3151820A4 (en) 2014-06-06 2017-11-22 Flexus Biosciences, Inc. Immunoregulatory agents
EP3151921B1 (en) 2014-06-06 2019-08-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2016014576A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
CN107001316A (en) 2014-08-06 2017-08-01 诺华股份有限公司 It is used as the Carbostyril derivative of antiseptic
JP6919118B2 (en) 2014-08-14 2021-08-18 ノバルティス アーゲー Treatment of cancer with GFRα-4 chimeric antigen receptor
CN106714833A (en) * 2014-08-15 2017-05-24 昂考梅德药品有限公司 Rspo1 binding agents and uses thereof
RU2020117196A (en) 2014-08-19 2020-10-15 Новартис Аг CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
EP3985394A1 (en) 2014-08-27 2022-04-20 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
RU2718914C2 (en) 2014-09-13 2020-04-15 Новартис Аг Combined treatment methods using alk inhibitors
CN106687137A (en) 2014-09-16 2017-05-17 昂考梅德药品有限公司 Treatment of fibrotic diseases
ES2891332T3 (en) 2014-09-17 2022-01-27 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP2017535528A (en) 2014-10-03 2017-11-30 ノバルティス アーゲー Combination therapy
KR20170062485A (en) * 2014-10-03 2017-06-07 다나-파버 캔서 인스티튜트 인크. Glucocorticoid-induced tumor necrosis factor receptor(gitr) antibodies and methods of use thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CN114107424A (en) 2014-10-08 2022-03-01 诺华股份有限公司 Biomarkers for predicting therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
KR102513870B1 (en) 2014-10-14 2023-03-23 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
SMT202100301T1 (en) 2014-10-29 2021-07-12 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
JP2017538678A (en) 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Immunomodulator
UY36391A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN107250157B (en) 2014-11-21 2021-06-29 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions
CA2968357A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
PL3233843T3 (en) 2014-12-16 2020-04-30 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
PE20221834A1 (en) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd ANTIMYOSTATIN ANTIBODIES
AR103232A1 (en) 2014-12-22 2017-04-26 Bristol Myers Squibb Co TGFbR ANTAGONISTS
KR102644115B1 (en) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Antibodies to tigit
CA2972597A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
TWI844507B (en) 2015-02-05 2024-06-11 日商中外製藥股份有限公司 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, and uses therof
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
AR103726A1 (en) 2015-02-27 2017-05-31 Merck Sharp & Dohme HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
JP6836998B2 (en) 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ， インコーポレイテッド TGF-β inhibitor
JP6692826B2 (en) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． Compositions and methods for activation of "interferon gene stimulator" dependent signaling
CN108093636A (en) 2015-04-03 2018-05-29 百时美施贵宝公司 Indoleamine 2, 3-dioxygenase inhibitors for the treatment of cancer
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TW201642897A (en) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 HER2 binding agent therapies
PT3280729T (en) 2015-04-08 2022-08-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
SI3283527T1 (en) 2015-04-13 2021-04-30 Five Prime Therapeutics, Inc. Combination therapy against cancer
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
PE20180394A1 (en) 2015-04-17 2018-02-28 Bristol Myers Squibb Co COMPOSITIONS INCLUDING A COMBINATION OF A PROGRAMMED ANTI DEATH ANTIBODY 1 (PD-1) AND ANOTHER ANTIBODY
JP7114457B2 (en) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US20190192565A1 (en) * 2015-06-03 2019-06-27 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JP6812364B2 (en) 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-GITR antibody for cancer diagnosis
EP3313886A1 (en) 2015-06-29 2018-05-02 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CN109476722A (en) 2015-07-21 2019-03-15 诺华股份有限公司 Methods for improving the efficacy and expansion of immune cells
WO2017015623A2 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
CN108137597A (en) 2015-07-28 2018-06-08 百时美施贵宝公司 Tgf beta receptor antagonists
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
LT3317301T (en) 2015-07-29 2021-07-26 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108349976A (en) 2015-08-25 2018-07-31 百时美施贵宝公司 TGF β receptor antagonists
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
JP6980649B2 (en) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド The solid form of the isoquinolinone derivative, the method for producing it, the composition containing it, and the method for using it.
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
HK1258509A1 (en) * 2015-10-22 2019-11-15 Ablynx Nv Gitr agonists
KR20180069903A (en) 2015-11-02 2018-06-25 파이브 프라임 테라퓨틱스, 인크. CD80 extracellular domain polypeptides and their use in the treatment of cancer
HRP20220436T1 (en) 2015-11-03 2022-05-27 Janssen Biotech, Inc. ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR USES
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
BR112018010410A8 (en) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc method for treating cancer in a subject, composition and methods of increasing the number of nk cells and increasing the number of one or more pd-11 positive cells
CN116063542A (en) 2015-12-02 2023-05-05 阿吉纳斯公司 Antibodies and methods of use thereof
CN108602829A (en) 2015-12-15 2018-09-28 百时美施贵宝公司 Cxcr4 receptor antagonists
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
KR20180089510A (en) 2015-12-18 2018-08-08 노파르티스 아게 Antibodies targeting CD32b and methods of using the same
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP2019500874A (en) 2015-12-28 2019-01-17 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
BR112018014150A2 (en) 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
BR112018016842A2 (en) 2016-02-19 2018-12-26 Novartis Ag tetracyclic pyridone compounds as antivirals
BR112018067679A2 (en) 2016-03-04 2019-01-15 Novartis Ag cells expressing multiple chimeric antigen receptor (car) molecules and their use
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
MA43814A (en) 2016-03-08 2018-11-28 Janssen Biotech Inc ANTI-GITR ANTIBODIES, METHODS AND USES
JP7034489B2 (en) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド Multispecific Fab fusion protein and its use
CN109069638B (en) 2016-03-24 2022-03-29 璟尚生物制药公司 Trispecific inhibitors for cancer therapy
CN109311885A (en) 2016-03-24 2019-02-05 诺华股份有限公司 Inhibitor of the alkynyl nucleoside analog as human rhinovirus
EP3442567A4 (en) 2016-04-13 2019-12-18 Orimabs Ltd. ANTI-PSMA ANTIBODIES AND THEIR USE
CN109348714A (en) 2016-05-04 2019-02-15 百时美施贵宝公司 The inhibitor and its application method of indole amine 2,3-dioxygenase
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190004742A (en) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 Inhibitors of indoleamine 2,3-dioxygenase and methods of use thereof
US10323004B2 (en) 2016-05-04 2019-06-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452030A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TWI822521B (en) 2016-05-13 2023-11-11 美商再生元醫藥公司 Methods of treating skin cancer by administering a pd-1 inhibitor
RS65474B1 (en) 2016-05-20 2024-05-31 Biohaven Therapeutics Ltd Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
US10071973B2 (en) 2016-06-14 2018-09-11 Novartis Ag Crystalline isoxazole hydroxamic acid compounds
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
IL263680B1 (en) 2016-06-24 2025-06-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
CN109641967A (en) 2016-07-01 2019-04-16 戊瑞治疗有限公司 With the combined antitumor therapy of GITR agonist and CpG
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
AU2017300788B2 (en) * 2016-07-22 2023-11-16 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
AU2017308734A1 (en) 2016-08-12 2019-02-14 Janssen Biotech, Inc. Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
US11077178B2 (en) 2016-09-21 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
EA037973B1 (en) * 2016-10-12 2021-06-18 Янссен Байотек, Инк. Gitr antibodies, methods and uses
TW201819380A (en) 2016-10-18 2018-06-01 瑞士商諾華公司 Fused tetracyclic pyridone compounds as antivirals
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
CA3041340A1 (en) * 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JOP20190100A1 (en) 2016-11-19 2019-05-01 Potenza Therapeutics Inc Anti-gitr antigen-binding proteins and methods of use thereof
RU2019120398A (en) 2016-12-03 2021-01-12 Джуно Терапьютикс, Инк. METHODS FOR DETERMINING CART CELLS DOSAGE
KR102312222B1 (en) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Monoclonal Antibodies Targeting Unique Sialoglycosylated Cancer-Associated Epitopes of CD43
CN116606261A (en) 2016-12-22 2023-08-18 美国安进公司 KRAS G12C inhibitors and methods of use thereof
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
EP3570844B1 (en) 2017-01-20 2023-09-06 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
SG11201906963QA (en) * 2017-01-27 2019-08-27 Ultrahuman One Ltd Binding agents
AU2018218324A1 (en) 2017-02-10 2019-08-22 Eutilex Co., Ltd. IFN-γ-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibody and uses thereof
CN110536905B (en) 2017-02-21 2023-10-27 瑞泽恩制药公司 Anti-PD-1 antibodies for lung cancer treatment
RU2019127550A (en) * 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. ANTI-GITR ANTIBODIES AND METHODS OF THEIR USE
AU2018243754B2 (en) 2017-03-31 2025-04-10 Bristol-Myers Squibb Company Methods of treating tumor
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AU2018249493A1 (en) 2017-04-03 2019-09-19 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
CA3057744A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
SG11201909710XA (en) 2017-04-21 2019-11-28 Kyn Therapeutics Indole ahr inhibitors and uses thereof
CN110621341A (en) 2017-04-26 2019-12-27 百时美施贵宝公司 Antibody production method that minimizes disulfide bond reduction
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
ES2899616T3 (en) 2017-04-28 2022-03-14 Five Prime Therapeutics Inc CD80 extracellular domain polypeptides for use in increasing central memory T cells
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
EA039583B1 (en) * 2017-05-02 2022-02-14 Регенерон Фармасьютикалз, Инк. Anti-gitr antibodies and uses thereof
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112019022873A8 (en) 2017-05-02 2023-04-11 Merck Sharp & Dohme FORMULATION, AND, INJECTION VESSEL OR DEVICE.
UY37718A (en) 2017-05-05 2018-11-30 Novartis Ag 2-TRYCLINAL QUINOLINONES AS ANTIBACTERIAL AGENTS
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN110869392A (en) 2017-05-16 2020-03-06 百时美施贵宝公司 Treatment of cancer with anti-GITR agonistic antibodies
WO2018213377A1 (en) 2017-05-17 2018-11-22 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
EP4098662A1 (en) 2017-05-25 2022-12-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
AU2018275109A1 (en) 2017-06-01 2020-01-02 Xencor, Inc. Bispecific antibodies that bind CD 123 CD3
MX2019014268A (en) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy.
EP3634584B1 (en) 2017-06-09 2024-09-18 Providence Health & Services - Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN109136275B (en) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized GITR gene modified animal model
CN110785187B (en) 2017-06-22 2024-04-05 诺华股份有限公司 Antibody molecules targeting CD73 and uses thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3061874A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
MX2019015738A (en) 2017-06-27 2020-02-20 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof.
MX2019015155A (en) 2017-06-29 2020-08-03 Juno Therapeutics Inc MOUSE MODEL TO ASSESS TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES.
WO2019001559A1 (en) 2017-06-30 2019-01-03 江苏恒瑞医药股份有限公司 Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EA202090119A1 (en) 2017-06-30 2020-04-21 Бристол-Маерс Сквибб Компани AMORPHIC AND CRYSTALLINE FORMS OF IDO INHIBITORS
JP2020527572A (en) 2017-07-20 2020-09-10 ノバルティス アーゲー Anti-LAG-3 antibody dosage regimen and its use
ES2932354T3 (en) 2017-07-28 2023-01-18 Bristol Myers Squibb Co Cyclic dinucleotides as anticancer agents
JP7670481B2 (en) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Bicyclic peptide ligands specific for CD137 - Patent application
KR20200051646A (en) 2017-08-17 2020-05-13 이케나 온콜로지, 인코포레이티드 AHR inhibitors and uses thereof
KR20240138135A (en) 2017-08-25 2024-09-20 파이브 프라임 테라퓨틱스, 인크. B7-h4 antibodies and methods of use thereof
CN111051328B (en) 2017-08-31 2023-11-03 百时美施贵宝公司 Cyclic dinucleotides as anticancer agents
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102651946B1 (en) 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotides as anticancer agents
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
MX2020003190A (en) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Protein degraders and uses thereof.
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
AU2018347582B2 (en) 2017-10-13 2025-08-28 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Methods of treating tumor
JP7254821B2 (en) 2017-10-16 2023-04-10 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US20200370012A1 (en) 2017-10-25 2020-11-26 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MA49911A (en) 2017-11-01 2020-06-24 Juno Therapeutics Inc ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN
TW201932482A (en) 2017-11-01 2019-08-16 美商奇諾治療有限公司 Chimeric antigen receptor and polynucleotide encoding specific for B cell maturation antigen
ES2925450T3 (en) 2017-11-06 2022-10-18 Bristol Myers Squibb Co Isofuranone compounds useful as HPK1 inhibitors
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
EP3710455A1 (en) 2017-11-17 2020-09-23 Novartis AG Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
MA51210A (en) 2017-12-01 2020-10-07 Juno Therapeutics Inc METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
CN112204048A (en) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 Anti-CCT5 binding molecules and methods of use
US11234977B2 (en) 2017-12-20 2022-02-01 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
CN111788227B (en) 2017-12-27 2025-02-25 百时美施贵宝公司 Anti-CD40 antibodies and uses thereof
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US10793563B2 (en) 2018-01-29 2020-10-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CA3091174A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
MX2020008791A (en) 2018-02-23 2021-01-08 Bicycletx Ltd Multimeric bicyclic peptide ligands.
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
MA52416A (en) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc B7-H4 ANTIBODIES AND PROCESSES FOR USE
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
US11945834B2 (en) 2018-03-08 2024-04-02 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3768716A1 (en) 2018-03-21 2021-01-27 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN110357958A (en) * 2018-03-26 2019-10-22 信达生物制药(苏州)有限公司 Miniaturization antibody, its polymer and the application of the Tumor Necrosis Factor Receptors (GITR) of Antiglucocorticoid induction
CN110305210B (en) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 Novel antibody molecules, methods of making and uses thereof
WO2019184909A1 (en) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 Novel antibody molecule, and preparation method and use thereof
CN111918873B (en) 2018-03-27 2025-06-24 百时美施贵宝公司 Real-time titer monitoring using UV signal
JP2021519771A (en) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ How to treat a tumor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
AU2019255196A1 (en) 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
CN110386981A (en) * 2018-04-20 2019-10-29 信达生物制药(苏州)有限公司 Anti- GITR antibody and application thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
MX2020010836A (en) 2018-05-04 2021-01-08 Amgen Inc Kras g12c inhibitors and methods of using the same.
AU2019262599B2 (en) 2018-05-04 2023-10-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MA52564A (en) 2018-05-10 2021-03-17 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
JP2021524449A (en) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム Molecular adjuvant
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TWI869346B (en) 2018-05-30 2025-01-11 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2020012731A (en) 2018-06-01 2021-02-22 Amgen Inc Kras g12c inhibitors and methods of using the same.
US20210205449A1 (en) 2018-06-01 2021-07-08 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
JP7369719B2 (en) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C inhibitors and methods of using the same
KR20210020932A (en) 2018-06-13 2021-02-24 노파르티스 아게 BCMA chimeric antigen receptor and uses thereof
CN112638375A (en) 2018-06-15 2021-04-09 旗舰创业创新五公司 Increasing immune activity through modulation of post-cellular signaling factors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
SMT202300466T1 (en) 2018-06-27 2024-01-10 Bristol Myers Squibb Co Substituted naphthyridinone compounds useful as t cell activators
EA202190137A1 (en) 2018-06-27 2021-05-17 Бристол-Маерс Сквибб Компани NAPHTHYRIDINE COMPOUNDS FOR USE AS T-CELL ACTIVATORS
JP2021532170A (en) 2018-06-29 2021-11-25 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. Trispecific antagonist
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
JP7411627B2 (en) 2018-07-09 2024-01-11 ファイヴ プライム セラピューティクス インク Antibody that binds to ILT4
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
HRP20231295T1 (en) 2018-07-10 2024-02-02 Novartis Ag 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2) DEPENDENT DISEASES
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
ES2982326T3 (en) 2018-07-27 2024-10-15 Arcus Biosciences Inc Pyridone A2R antagonists
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
LT3844267T (en) 2018-08-31 2025-10-10 Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR102846109B1 (en) 2018-09-07 2025-08-18 화이자 인코포레이티드 Anti-αvβ8 antibody and composition and use thereof
CN113164419A (en) 2018-09-07 2021-07-23 皮克医疗公司 EIF4E inhibitors and uses thereof
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020065453A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
TW202028245A (en) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3 single domain antibodies and therapeutic compositions thereof
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN119569895A (en) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G protein coupled receptor class C group 5 member D (GPRC 5D) specific chimeric antigen receptor
JP7503056B6 (en) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー Co-formulation of anti-LAG3 and anti-PD-1 antibodies
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR102718333B1 (en) 2018-11-16 2024-10-17 아르커스 바이오사이언시즈 인코포레이티드 Inhibitors of ARG1 and/or ARG2
MX2021005734A (en) 2018-11-16 2021-09-10 Juno Therapeutics Inc METHODS OF DOSING MODIFIED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES.
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP2022513653A (en) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー Antibodies containing modified heavy chain constant regions
EP3886875B1 (en) 2018-11-30 2024-05-08 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
BR112021010484A2 (en) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Irak degraders and their uses
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
AU2019403488B2 (en) 2018-12-20 2025-07-24 Amgen Inc. KIF18A inhibitors
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
MA54546A (en) 2018-12-20 2022-03-30 Amgen Inc HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
CN120398830A (en) 2018-12-20 2025-08-01 美国安进公司 KIF18A inhibitors
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
JP2022516850A (en) 2018-12-21 2022-03-03 ノバルティス アーゲー Use of IL-1β antibody in the treatment or prevention of myelodysplastic syndrome
JP7678753B2 (en) 2019-01-29 2025-05-16 ジュノー セラピューティクス インコーポレイテッド Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1 (ROR1)
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (en) 2019-02-15 2024-05-15 ノバルティス アーゲー 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
KR20210146287A (en) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. Bicyclic heteroaryl compounds and uses thereof
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US20220241313A1 (en) 2019-03-12 2022-08-04 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
TW202102542A (en) 2019-03-19 2021-01-16 瓦爾希伯倫私人腫瘤研究基金會 Combination therapy for the treatment of cancer
JP7743309B2 (en) 2019-03-29 2025-09-24 アーカス バイオサイエンシズ インコーポレイティド Cancer treatment using identified adenosine fingerprints
EP3946437A1 (en) 2019-03-29 2022-02-09 Myst Therapeutics, LLC Ex vivo methods for producing a t cell therapeutic and related compositions and methods
AU2020253990A1 (en) 2019-04-02 2021-10-28 Bicycletx Limited Bicycle toxin conjugates and uses thereof
BR112021019748A2 (en) 2019-04-05 2021-12-07 Kymera Therapeutics Inc Stat degraders and their uses
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
RU2734432C1 (en) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
UA129871C2 (en) 2019-05-21 2025-08-27 Емджен Інк. SOLID FORMS
KR20220012292A (en) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 How to monitor cell culture media
CN114174537A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Cell localization features and combination therapies
JP2022534967A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Multiple tumor gene signatures and their uses
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
MX2021014441A (en) 2019-05-31 2022-01-06 Ikena Oncology Inc Tead inhibitors and uses thereof.
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
CN114401953A (en) 2019-08-02 2022-04-26 美国安进公司 KIF18A inhibitors
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
CA3147451A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (en) 2019-08-28 2022-01-12 Bristol Myers Squibb Co SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
PH12022550605A1 (en) 2019-09-13 2023-09-25 Nimbus Saturn Inc Hpk1 antagonists and uses thereof
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
BR112022004831A2 (en) 2019-09-19 2022-06-07 Bristol Myers Squibb Co Antibodies that bind to seen at acidic pH
KR20220070005A (en) 2019-09-26 2022-05-27 노파르티스 아게 Antiviral pyrazolopyridinone compounds
US20240301054A1 (en) 2019-10-21 2024-09-12 Novartis Ag Tim-3 inhibitors and uses thereof
BR112022007376A2 (en) 2019-10-21 2022-07-05 Novartis Ag COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
JP2022553859A (en) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド RAS inhibitor
CR20220240A (en) 2019-11-04 2022-08-03 Revolution Medicines Inc RAS INHIBITORS
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
EP4058453A1 (en) 2019-11-14 2022-09-21 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
KR20220103753A (en) 2019-11-19 2022-07-22 브리스톨-마이어스 스큅 컴퍼니 Compounds useful as inhibitors of helios proteins
AU2020393854A1 (en) 2019-11-26 2022-06-09 Bristol-Myers Squibb Company Salts/cocrystals of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
EP4065157A1 (en) 2019-11-26 2022-10-05 Novartis AG Cd19 and cd22 chimeric antigen receptors and uses thereof
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
ES3028099T3 (en) 2019-11-26 2025-06-18 Ikena Oncology Inc Polymorphic carbazole derivatives and uses thereof
AU2020391231A1 (en) 2019-11-27 2022-07-14 Turnstone Biologics Corp. Method of producing tumor-reactive T cell composition using modulatory agents
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
BR112022011651A2 (en) 2019-12-17 2022-08-23 Kymera Therapeutics Inc IRAK DEGRADATORS AND USES THEREOF
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
MX2022007369A (en) 2019-12-23 2022-07-12 Bristol Myers Squibb Co SUBSTITUTED PIPERAZINE QUINOLINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS.
AR120823A1 (en) 2019-12-23 2022-03-23 Bristol Myers Squibb Co SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS
AU2020415377A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as T cell activators
ES3013568T3 (en) 2019-12-23 2025-04-14 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
IL294270A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted piperazine derivatives are useful as t-cell activators
CN115297931A (en) 2019-12-23 2022-11-04 凯麦拉医疗公司 SMARCA degraders and their uses
BR112022013424A2 (en) 2020-01-06 2022-12-13 Hifibio Hk Ltd ANTI-TNFR2 ANTIBODY AND ITS USES
CN115210261B (en) 2020-01-07 2025-07-18 高诚生物医药公司 Anti-galectin-9 antibodies and uses thereof
CN114929279A (en) 2020-01-07 2022-08-19 锐新医药公司 Methods of administering SHP2 inhibitors and treating cancer
BR112022012310A2 (en) 2020-01-17 2022-09-06 Novartis Ag A COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETYLING AGENT FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
WO2021163618A1 (en) 2020-02-14 2021-08-19 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
KR20220147109A (en) 2020-02-27 2022-11-02 노파르티스 아게 Methods for making chimeric antigen receptor-expressing cells
KR20220158727A (en) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 Methods for enriching and expanding tumor-reactive T cells ex vivo and compositions related thereto
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP4114859A1 (en) 2020-03-06 2023-01-11 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
KR20220151189A (en) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 Antibodies to CD40 with enhanced agonist activity
US20240424110A1 (en) 2020-03-19 2024-12-26 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
US11407712B2 (en) 2020-03-19 2022-08-09 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
TW202140441A (en) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 Substituted oxoisoindoline compounds
US20230149462A1 (en) 2020-04-10 2023-05-18 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CR20220611A (en) 2020-06-02 2023-06-07 Arcus Biosciences Inc ANTI-TIGIT ANTIBODIES
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
BR112022026202A2 (en) 2020-06-23 2023-01-17 Novartis Ag DOSAGE REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN116133692A (en) 2020-07-30 2023-05-16 凯麦拉医疗公司 Methods of treating mutant lymphomas
CN116134027B (en) 2020-08-03 2025-01-24 诺华股份有限公司 Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2023001707A (en) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8.
JP2023538906A (en) 2020-08-17 2023-09-12 バイシクルティーエクス・リミテッド Bicyclic conjugates specific for nectin-4 and uses thereof
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230303700A1 (en) 2020-08-31 2023-09-28 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
CN116209438A (en) 2020-09-03 2023-06-02 锐新医药公司 Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors
CN116457358A (en) 2020-09-15 2023-07-18 锐新医药公司 Indole derivatives as RAS inhibitors for the treatment of cancer
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
MX2023005609A (en) 2020-11-13 2023-05-29 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells.
WO2022111571A1 (en) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 Tumor infiltration lymphocyte culture medium and application thereof
CN116761606A (en) 2020-11-25 2023-09-15 上海君赛生物科技有限公司 Pharmaceutical composition for enhancing cell killing and application thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
IL303376A (en) 2020-12-02 2023-08-01 Ikena Oncology Inc TEAD inhibitors and their uses
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20240050432A1 (en) 2020-12-08 2024-02-15 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
CN117396472A (en) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 SOS1 inhibitors and uses thereof
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
ES3023507T3 (en) 2020-12-28 2025-06-02 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN116761622A (en) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 Pharmaceutical product and use thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
TW202246334A (en) 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr antagonists and methods of using the same
CA3206501A1 (en) 2021-02-02 2022-08-11 Shaun Abbott Gpr84 antagonists and uses thereof
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
US12252488B2 (en) 2021-02-12 2025-03-18 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
MX2023009379A (en) 2021-02-12 2023-10-10 Hoffmann La Roche Bicyclic tetrahydroazepine derivatives for the treatment of cancer.
MX2023009527A (en) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Irak4 degraders and uses thereof.
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024509192A (en) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド HPK1 antagonists and their uses
JP2024510176A (en) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション MAP4K1 inhibitor
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
JP2024513011A (en) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド HPK1 antagonists and their uses
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JP2024514530A (en) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Antibodies against truncated CDCP1 and uses thereof
JP2024515545A (en) 2021-04-05 2024-04-10 ブリストル－マイヤーズ スクイブ カンパニー Pyridinyl-substituted oxoisoindoline compounds for cancer treatment
PL4320112T3 (en) 2021-04-06 2025-07-21 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL307479A (en) 2021-04-09 2023-12-01 Nimbus Clio Inc Modulators of CBL-B and their uses
EP4323066A1 (en) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CN117500811A (en) 2021-05-05 2024-02-02 锐新医药公司 Covalent RAS inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR125782A1 (en) 2021-05-05 2023-08-16 Revolution Medicines Inc RAS INHIBITORS
PH12023500023A1 (en) 2021-05-07 2024-03-11 Kymera Therapeutics Inc Cdk2 degraders and uses thereof
JP7671092B2 (en) * 2021-05-10 2025-05-01 メディマブバイオ インコーポレイテッド Anti-GITR antibodies and uses thereof
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
JP2024521712A (en) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド AXL Inhibitor Compounds
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
TW202307210A (en) 2021-06-01 2023-02-16 瑞士商諾華公司 Cd19 and cd22 chimeric antigen receptors and uses thereof
EP4351595A1 (en) 2021-06-07 2024-04-17 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
JP2024525475A (en) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Engineered immune cells to promote tanotransmission and uses thereof
EP4370523A1 (en) 2021-07-14 2024-05-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
JP2024532276A (en) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド eIF4E inhibitors and uses thereof
JP2024534127A (en) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド eIF4E inhibitors and uses thereof
WO2023039089A1 (en) 2021-09-08 2023-03-16 Twentyeight-Seven, Inc. Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
EP4423069A1 (en) 2021-10-29 2024-09-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
JP2024540080A (en) 2021-10-29 2024-10-31 カイメラ セラピューティクス， インコーポレイテッド IRAK4 degraders and their synthesis
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
JP2025500878A (en) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション PYRAZOLO-PYRAZINE COMPOUNDS AS SHP2 INHIBITORS
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
TW202339738A (en) 2022-01-31 2023-10-16 美商凱麥拉醫療公司 Irak degraders and uses thereof
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023154905A1 (en) 2022-02-14 2023-08-17 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Methods for treating immune-refractory lung cancer
US20250188152A1 (en) 2022-03-09 2025-06-12 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US20250179204A1 (en) 2022-03-15 2025-06-05 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
KR20240144422A (en) 2022-03-15 2024-10-02 컴퓨젠 엘티디. IL-18BP antagonist antibodies and their uses in monotherapy and combination therapy for cancer treatment
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
KR20250006959A (en) 2022-05-02 2025-01-13 아르커스 바이오사이언시즈 인코포레이티드 Anti-TIGIT antibodies and uses thereof
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
JP2025519119A (en) 2022-05-25 2025-06-24 イケナ オンコロジー， インコーポレイテッド MEK inhibitors and their uses
JP2025518785A (en) 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー Antibody compositions and methods of use thereof
KR20250022133A (en) 2022-06-10 2025-02-14 레볼루션 메디슨즈, 인크. macrocyclic RAS inhibitors
KR20250029137A (en) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Treatment methods for second-line therapy with CD19-targeted CAR T cells
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN120051456A (en) 2022-08-02 2025-05-27 里米诺生物科学有限公司 Substituted pyridone GPR84 antagonists and uses thereof
TW202415650A (en) 2022-08-02 2024-04-16 英商利米那生物科技有限公司 Aryl-triazolyl and related gpr84 antagonists and uses thereof
AU2023317740A1 (en) 2022-08-02 2025-03-13 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
IL318416A (en) 2022-08-05 2025-03-01 Juno Therapeutics Inc Chimeric antigen receptors specific for gprc5d and bcma
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
PE20251399A1 (en) 2022-08-11 2025-05-22 Hoffmann La Roche Bicyclic tetrahydrothiazepine derivatives
EP4568960A1 (en) 2022-08-11 2025-06-18 F. Hoffmann-La Roche AG Bicyclic tetrahydroazepine derivatives
JP2025526683A (en) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bicyclic tetrahydrothiazepine derivatives
AU2023322638A1 (en) 2022-08-11 2024-11-28 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
JP2025531079A (en) 2022-09-14 2025-09-19 アーカス バイオサイエンシズ インコーポレイティド Dispersion of Etrumadenant
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
PE20251879A1 (en) 2022-10-14 2025-07-22 Black Diamond Therapeutics Inc Cancer treatment methods using isoquinoline or 6-azaquinoline derivatives
CN120091809A (en) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Lyophilized formulations of CD73 compounds
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
TW202504611A (en) 2023-03-30 2025-02-01 美商銳新醫藥公司 Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4511371A1 (en) 2023-05-08 2025-02-26 Bristol-Myers Squibb Company Substituted phenyl oxazolone compounds
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
US20250059164A1 (en) 2023-06-23 2025-02-20 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202515608A (en) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
WO2025049840A1 (en) 2023-09-02 2025-03-06 Bristol-Myers Squibb Company Substituted phenyl oxooxazolyl piperidine dione compounds
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
US20250084056A1 (en) 2023-09-13 2025-03-13 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
US20250230173A1 (en) 2023-12-20 2025-07-17 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
FI903489A7 (en) 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE452975T1 (en) 1992-08-21 2010-01-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAINS
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
EP0920505B1 (en) 1996-08-16 2008-06-04 Schering Corporation Mammalian cell surface antigens; related reagents
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
CA2308114A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (en) * 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AU3860100A (en) 1999-02-24 2000-09-14 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US20020010320A1 (en) * 1999-04-05 2002-01-24 James W. Fett Chemeric and humanized antibodies to angiogenin
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
IL147442A0 (en) 1999-07-12 2002-08-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
EP1292680B1 (en) * 2000-06-22 2009-10-21 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
JP4414142B2 (en) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Specific binding proteins and uses thereof
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
US6701566B2 (en) * 2001-07-26 2004-03-09 Craig T. Rooke Trailer electrical connector cleaning system
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2003046009A1 (en) * 2001-11-27 2003-06-05 Mochida Pharmaceutical Co., Ltd. ANTI-IL13 RECEPTOR α1 NEUTRALIZING ANTIBODY
WO2003048730A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7438911B2 (en) * 2002-04-30 2008-10-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
US20040110930A1 (en) 2002-10-03 2004-06-10 Reinl Stephen J. Multimeric protein engineering
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
PT1578446E (en) * 2002-11-07 2015-07-22 Immunogen Inc Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
US20060099143A1 (en) * 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
JPWO2004065418A1 (en) 2003-01-20 2006-06-29 中外製薬株式会社 Anti-PCI neutralizing antibody
MXPA05007853A (en) * 2003-01-24 2006-02-10 Applied Molecular Evolution Human il-1 beta antagonists.
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
CN1809589A (en) * 2003-05-23 2006-07-26 Wyeth公司 GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
JP4638876B2 (en) 2003-05-23 2011-02-23 ワイス GITR ligand, GITR ligand-related molecule and antibody and use thereof
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
EP1629005A2 (en) * 2003-05-30 2006-03-01 Intercell AG Enterococcus antigens
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
EP1670827A2 (en) * 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP2330201B1 (en) 2003-10-22 2017-04-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
ES2357430T3 (en) 2003-10-24 2011-04-26 Immunaid Pty Ltd THERAPY METHOD
CA2545756A1 (en) 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
PE20050925A1 (en) 2003-11-10 2005-11-29 Schering Corp RECOMBINANT ANTI-INTERLEUQUIN HUMANIZED ANTIBODY 10
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
CA2549800A1 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
US20050153872A1 (en) * 2004-01-12 2005-07-14 Xiao-Qing Qiu Methods and compositions for the treatment of infection
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
EP1765402A2 (en) * 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
ATE546733T1 (en) 2004-09-08 2012-03-15 Immunaid Pty Ltd THERAPY STRATEGY FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND DEGENERATIVE DISEASES
JP2008520186A (en) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Novel antibody against mammalian EAG1 ion channel protein
KR20070094890A (en) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 Anti-ADL antibody and uses thereof
WO2006067847A1 (en) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha Method of preparing antibody by use of cell having its fucose transporter function inhibited
BRPI0606685A2 (en) 2005-01-19 2009-07-14 Genzyme Corp gitr antibodies for diagnosis of nsclc
KR101385886B1 (en) 2005-02-03 2014-04-24 안티토페 리미티드 Human antibodies and proteins
JP2008532559A (en) * 2005-03-19 2008-08-21 メディカル リサーチ カウンシル Treatment and prevention of viral infection or improvement of treatment and prevention
PT2343320T (en) * 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
JP2006278814A (en) 2005-03-30 2006-10-12 Konica Minolta Opto Inc Structure and method for circuit connection
KR101188117B1 (en) 2005-03-31 2012-10-09 바이오메딕스 인코포레이티드 Anti-CD-20 monoclonal antibody
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
US8252905B2 (en) * 2005-06-03 2012-08-28 Mochida Pharmaceutical Co., Ltd. Anti-CD14 antibody fusion protein
WO2006132272A1 (en) 2005-06-07 2006-12-14 The University Of Tokyo Method for production of antibody
WO2006137354A1 (en) * 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
GB0514319D0 (en) * 2005-07-13 2006-06-14 Secr Defence Antibodies for anthrax
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
CA2652392C (en) 2006-05-19 2017-10-10 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
WO2008019131A2 (en) * 2006-08-04 2008-02-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treating ige-mediated diseases
WO2008022295A2 (en) 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
ES2383710T3 (en) 2006-09-08 2012-06-25 Medimmune, Llc Humanized anti-CD19 antibodies and their use in the treatment of tumors, transplants and autoimmune diseases
JP2008278814A (en) * 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk Release of immune control by agonistic anti-human GITR antibody and its application
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
BRPI0817257A2 (en) 2007-09-24 2015-06-16 Univ Vanderbilt Monoclonal antibodies to respiratory syncytial virus and their uses
ES2788869T3 (en) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anti-GITR antibodies
SG10201501784YA (en) 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
EP3798237A1 (en) 2010-03-05 2021-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
AU2012329091A1 (en) 2011-10-28 2014-05-01 Merck Sharp & Dohme Corp. Engineered lower eukaryotic host strains for recombinant protein expression
KR101566539B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th2 cell and use thereof
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins

Also Published As

Publication number Publication date
US20170355772A1 (en) 2017-12-14
RU2646139C1 (en) 2018-03-01
CN103951753A (en) 2014-07-30
MX340953B (en) 2016-07-29
US9701751B2 (en) 2017-07-11
US20140348841A1 (en) 2014-11-27
EP2473531A1 (en) 2012-07-11
RU2012112829A (en) 2013-10-10
CA3067609A1 (en) 2011-03-10
US8709424B2 (en) 2014-04-29
AU2010289677A1 (en) 2012-04-05
ES2788869T3 (en) 2020-10-23
HRP20200720T1 (en) 2020-10-16
JP2013503632A (en) 2013-02-04
JP2016146834A (en) 2016-08-18
CA2772613C (en) 2020-03-10
CN102574924A (en) 2012-07-11
US20120189639A1 (en) 2012-07-26
MX2012002697A (en) 2012-06-25
WO2011028683A1 (en) 2011-03-10
PL3023438T3 (en) 2020-07-27
AU2010289677B2 (en) 2014-07-31
PT3023438T (en) 2020-05-08
KR101790802B1 (en) 2017-10-27
CA2772613A1 (en) 2011-03-10
CY1123404T1 (en) 2021-12-31
HUE049825T2 (en) 2020-10-28
DK3023438T3 (en) 2020-05-11
BR112012004823B1 (en) 2021-11-30
JP2017195893A (en) 2017-11-02
BR112012004823A2 (en) 2016-08-16
LT3023438T (en) 2020-05-11
EP2473531A4 (en) 2013-05-01
SG178991A1 (en) 2012-04-27
SI3023438T1 (en) 2020-07-31
EP3023438A1 (en) 2016-05-25
CN103951753B (en) 2018-01-12
JP6294585B2 (en) 2018-03-20
IN2015DN02826A (en) 2015-09-11
KR20120059603A (en) 2012-06-08
BR112012004823A8 (en) 2017-10-03
US10400040B2 (en) 2019-09-03
RU2595409C2 (en) 2016-08-27
KR20170119746A (en) 2017-10-27
EP3023438B1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
IN2015DN02826A (en)
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2009009079A (en) Engineered anti-il-23p19 antibodies.
MX2009009080A (en) Engineered anti-il-23p19 antibodies.
MX2009009283A (en) Engineered anti-il-23r antibodies.
MX2009011500A (en) Anti-mdl-1 antibodies.
PH12017501139A1 (en) Novel modulators and methods of use
ZA201207377B (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
MX344521B (en) Heterocycle amines and uses thereof.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MX364200B (en) Novel compositions and methods for the treatment of immune related diseases.
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MY185016A (en) Progenitor cells of mesodermal lineage
PH12013500379A1 (en) Notum protein modulators and methods of use
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
IL207310A0 (en) Vaccine compositions
MX357166B (en) Antibodies to notum pectinacetylesterase.
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA201308256B (en) Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures
MX2013012551A (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain
WO2011031833A3 (en) Human anti-cancer antibodies
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UA56675U (en) Method for local treatment generalized periodontitis using using singlent-oxygen therapy